iBio Announces Participation in the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

iBio, Inc. (NYSE: IBIO) announced its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will provide a pre-recorded presentation accessible to all registered attendees and on its website beginning January 10. iBio specializes in next-generation biopharmaceuticals through its FastPharming Manufacturing System, which integrates vertical farming and automated hydroponics to produce high-quality proteins. The firm is focused on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases.

Positive

• Participation in the H.C. Wainwright BioConnect Conference provides visibility and networking opportunities.
• The pre-recorded presentation can engage a broader audience, showcasing iBio's innovative technologies.
• iBio's FastPharming Manufacturing System positions the company as a leader in sustainable biologics manufacturing.

Negative

• None.

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System^®, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, January 10, 2022, the presentation will also be available on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System^® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, antigens, and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services^™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When is iBio participating in the H.C. Wainwright BioConnect Conference?

iBio will participate in the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

Where can I find iBio's presentation from the BioConnect Conference?

iBio's pre-recorded presentation will be available on their website starting January 10, 2022.

What is the focus of iBio's FastPharming Manufacturing System?

The FastPharming Manufacturing System focuses on sustainable, plant-based production of high-quality proteins for biopharmaceuticals.

What diseases is iBio developing treatments for?

iBio is developing treatments for cancers, fibrotic diseases, and infectious diseases.